

**NOVOGEN LIMITED**

**31 DECEMBER 2013**

**INTERIM FINANCIAL REPORT  
APPENDIX 4D**

**ASX Code: NRT**



---

## **DIRECTORS' REVIEW OF THE PRELIMINARY FINAL REPORT**

### **OPERATING AND FINANCIAL REVIEW**

#### **Review of financial condition**

The consolidated entity produced a net loss after taxation, attributable to the owners of Novogen Limited of \$3,055,263 (2012: profit of \$495,877).

Net Tangible Assets of the consolidated entity as at 31 December 2013 were \$2,537,565 (30 June 2013 \$1,510,480), or 1.57 cents per share (30 June 2013 1.09 cents).

#### **Review of principal business**

Since its inception in 1994, the principal business of Novogen has been pharmaceutical drug development.

From 1 July 2013 Novogen has been focused on the development of its super-benzopyran drug technology platform, with a particular attention on developing treatments for late-stage ovarian cancer and glioblastoma multiforme, the main form of primary brain cancer.

On 9 October 2013, Novogen announced the purchase of a second anti-cancer drug technology known as anti-tropomyosins. This was acquired from Australian private biotechnology company, Genscreen Pty Ltd. Since that acquisition, the company has focused on the identification of the intellectual property assets and lodgement of a series of provisional patents.

On 7 November 2014 Novogen entered into a joint venture company, CanTx. Inc, with Yale University. The joint venture represented a pooling of resources in the field of development of drugs to treat ovarian cancer. CanTx is a 85% subsidiary of Novogen and is based in New Haven, CT.

The stated goal of the company is to provide the technology and drugs capable of covering a wide range of different cancer cell genotypes and phenotypes that will permit the optimisation of chemotherapy on an individual basis. The company's research and development efforts are directed towards this goal.



Graham Kelly  
Chairman

27 February 2014  
Sydney

### 1. Company details

Name of entity:	Novogen Limited
ABN:	37 063 259 754
Reporting period:	For the half-year ended 31 December 2013
Previous period:	For the half-year ended 31 December 2012

### 2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	95.2% to	29,206
Loss from ordinary activities after tax attributable to the owners of Novogen Limited	down	716.1% to	(3,055,263)
Loss for the half-year attributable to the owners of Novogen Limited	down	716.1% to	(3,055,263)

#### *Dividends*

There were no dividends paid, recommended or declared during the current financial period.

#### *Comments*

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$3,055,263 (31 December 2012: profit of \$495,877).

For detailed commentary on results for the financial half-year, refer to operating and financial review preceding this Appendix 4D.

### 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>1.57</u>	<u>1.09</u>

### 4. Control gained over entities

Not applicable.

### 5. Loss of control over entities

Not applicable.

### 6. Dividends

#### *Current period*

There were no dividends paid, recommended or declared during the current financial period.

#### *Previous period*

On 27 November 2012, a dividend of \$24,774,709 was paid via an in-specie distribution of shares in MEI Pharma, Inc. representing 23.87 cents per ordinary share.

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

*Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and an unqualified review report, with an emphasis of matter with respect to going concern, is attached as part of the Interim Report.

---

## 11. Attachments

*Details of attachments (if any):*

The Interim Report of Novogen Limited for the half-year ended 31 December 2013 is attached.

---

## 12. Signed

Signed



---

Graham Kelly  
Chairman  
Sydney

Date: 27 February 2014